Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Denis Mulleman

Showing results (41-50 of 98) with videos related to

Pageof 10
Sort By:
Therapeutic Drug Monitoring|April 22, 2006
An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximabDavid Ternant, Denis Mulleman, Danielle Degenne, et al.
Arthritis Research & Therapy|November 27, 2009
Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritisDenis Mulleman, Jean-Camille Méric, Gilles Paintaud, et al.
Clinical Pharmacokinetics|October 6, 2019
Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial RevisitedAmina Bensalem, Denis Mulleman, Gilles Paintaud, et al.
Joint Bone Spine|June 9, 2016
Comparison of the Big Five personality traits in fibromyalgia and other rheumatic diseasesEmilie Bucourt, Virginie Martaillé, Denis Mulleman, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 29, 2016
Brief Report: Relationship Between Serum Infliximab Concentrations and Risk of Infections in Patients Treated for SpondyloarthritisTheodora Bejan-Angoulvant, David Ternant, Fadela Daoued, et al.
Joint Bone Spine|March 18, 2015
F-18 fluorodeoxyglucose positron emission tomography can detect early response to adalimumab, a tumor necrosis factor-α antagonist, in rheumatoid arthritis: A prospective pilot studySoujanya Ratna Edupuganti, Véronique Eder, David Ternant, et al.
European Spine Journal : Official Publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society|March 17, 2004
Primary amyloidoma of the axis and acute spinal cord compression: a case reportDenis Mulleman, René-Marc Flipo, Richard Assaker, et al.
Rheumatology International|June 14, 2021
Machine learning reveals the most important psychological and social variables predicting the differential diagnosis of rheumatic and musculoskeletal diseasesGermano Vera Cruz, Emilie Bucourt, Christian Réveillère, et al.
Pain Medicine (Malden, Mass.)|November 12, 2019
A Comparative Study of Fibromyalgia, Rheumatoid Arthritis, Spondyloarthritis, and Sjögren's Syndrome; Impact of the Disease on Quality of Life, Psychological Adjustment, and Use of Coping StrategiesEmilie Bucourt, Virginie Martaillé, Philippe Goupille, et al.
Arthritis Research & Therapy|June 29, 2011
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseasesEmilie Ducourau, Denis Mulleman, Gilles Paintaud, et al.
Pageof 10

Showing results (41-50 of 98) with videos related to

Sort By:
Pageof 10
Therapeutic Drug Monitoring|April 22, 2006
An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximabDavid Ternant, Denis Mulleman, Danielle Degenne, et al.
Arthritis Research & Therapy|November 27, 2009
Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritisDenis Mulleman, Jean-Camille Méric, Gilles Paintaud, et al.
Clinical Pharmacokinetics|October 6, 2019
Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial RevisitedAmina Bensalem, Denis Mulleman, Gilles Paintaud, et al.
Joint Bone Spine|June 9, 2016
Comparison of the Big Five personality traits in fibromyalgia and other rheumatic diseasesEmilie Bucourt, Virginie Martaillé, Denis Mulleman, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 29, 2016
Brief Report: Relationship Between Serum Infliximab Concentrations and Risk of Infections in Patients Treated for SpondyloarthritisTheodora Bejan-Angoulvant, David Ternant, Fadela Daoued, et al.
Joint Bone Spine|March 18, 2015
F-18 fluorodeoxyglucose positron emission tomography can detect early response to adalimumab, a tumor necrosis factor-α antagonist, in rheumatoid arthritis: A prospective pilot studySoujanya Ratna Edupuganti, Véronique Eder, David Ternant, et al.
European Spine Journal : Official Publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society|March 17, 2004
Primary amyloidoma of the axis and acute spinal cord compression: a case reportDenis Mulleman, René-Marc Flipo, Richard Assaker, et al.
Rheumatology International|June 14, 2021
Machine learning reveals the most important psychological and social variables predicting the differential diagnosis of rheumatic and musculoskeletal diseasesGermano Vera Cruz, Emilie Bucourt, Christian Réveillère, et al.
Pain Medicine (Malden, Mass.)|November 12, 2019
A Comparative Study of Fibromyalgia, Rheumatoid Arthritis, Spondyloarthritis, and Sjögren's Syndrome; Impact of the Disease on Quality of Life, Psychological Adjustment, and Use of Coping StrategiesEmilie Bucourt, Virginie Martaillé, Philippe Goupille, et al.
Arthritis Research & Therapy|June 29, 2011
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseasesEmilie Ducourau, Denis Mulleman, Gilles Paintaud, et al.
Pageof 10